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Identity 
Other names: FLJ12388, SIAL3 




The NEU3 gene spans 22 kb, consists of 4 exons and 3 
introns. It is a member of sialidase family consisting of 
NEU1, NEU2, NEU3, and NEU4. 
Transcription 
Northern blot analysis reveals 2.5 kb and 7 kb 
transcripts of NEU3 gene, possessing a common open 
reading frame of 1284 bp. NEU3 gene expression is 
diversely regulated by Sp1/Sp3 transcription factors 
which are recently considered to play critical roles in 
regulating the transcription of genes involved in cell 
growth and tumorigenesis. 
Protein 
Description 
Deduced amino acid sequence of human NEU3 
comprises of 428 amino acids and contains RIP box at 
N-terminal region and three Asp boxes in the center of 
the amino acid sequence. These motifs are commonly 
found in sialidases of microorganisms and vertebrates. 
The RIP motif is a part of active site and mutation of 
this motif led to decreased enzymatic activity. The Asp 
box is thought to participate in proper 3D structure 
formation of NEU3. 
Expression 
The gene is ubiquitously expressed with relatively 
higher levels in skeletal muscle, heart, and testis. The 
expression is upregulated during tumorigenesis, 
neuronal differentiation, T cell activation, and 
monocyte differentiation. Abnormal upregulation of 
NEU3 is observed in various  
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human neoplasms including colon, renal, ovarian and 
prostate cancers, except for the down-regulation in 
acute lymphoblastic leukemia. 
It is interesting to note that the transgenic mice 
ectopically expressing human NEU3 develop impaired 
insulin signaling and insulin-resistant diabetes mellitus 
by 18-22 weeks. 
Localisation 
Biochemical fractionation shows NEU3 to be localized 
in membrane fractions, especially in raft or caveolae 
membrane microdomains. In immuno- fluorescence 
studies, the bovine and mouse Neu3 sialidases are 
mostly detected on the cell surface, but the human 
NEU3 may exist also in other cellular membrane 
components and can mobilize to membrane ruffles 
together with Rac-1 in response to growth stimuli such 
as EGF, enhancing cell movement. 
Function 
NEU3 sialidase removes sialic acid moiety of 
gangliosides. It hardly acts on glycoproteins, 
oligosaccharides, and an artificial substrate 4MU-
NeuAc. NEU3 alters gangliosides composition of 
tissues and cells, and leads to modulation of signal 
transduction such as EGFR (epidermal growth factor 
receptor) and IR (insulin receptor) signaling. Besides, 
NEU3 has been shown to associate with signaling 
molecules including EGFR, Grb2, caveolin-1, and Rac. 
In addition to the catalytic reaction as a sialidase, the 
interaction with the protein molecules may also give an 
influence on the NEU3 function. Disturbance of 
signaling by abnormal upregulation of NEU3 is likely a 
possible cause of tumorigenesis or diabetes mellitus. 
Homology 
The NEU3 amino acid sequence shows 28% identity to 
NEU1, 42% to NEU2, and 45% to NEU4. NEU3 




NEU3 shows higher enzymatic activity and mRNA 
level in colon tumors as compared to adjacent normal 
mucosa. In tumor cells, lactosylceramide, one of the 
products of NEU3 enzymatic reaction, accumulates in 
tumor cells. Over expression of NEU3 or exogenous 
addition of lactosylceramide to the cell culture confer 
resistance to sodium butyrate-induced apoptosis. On 
the other hand, silencing of NEU3 by siRNA causes 
induction of apoptosis in cancer cells accompanied 
with suppression of EGFR signaling, suggesting that 
survival of tumor cells is addictive to NEU3 
expression. Interestingly, NEU3-knock down in normal 
cells including primary culture of keratinocytes or 
fibroblasts does not cause growth arrest nor apoptosis. 
Transgenic mice ectopically expressing human NEU3 
shows upregulation of EGFR signaling, lower 
induction of apoptosis, and high incidence of ACF 
(aberrant crypt foci) formation in colon mucosa cells 
upon administration of azoxymethane (AOM), a 
carcinogen for colonic tumorigenesis. 
Renal cell carcinoma 
Note 
Renal cell carcinoma shows upregulation of NEU3 
along with high expression of IL6. IL6 appears to 
increase NEU3 gene expression in ACHN cells, and the 
increase brings about enhanced activation of PI3K and 
Akt upon IL6 administration, resulting in suppression 
of apoptosis. 
Type II diabetes mellitus 
Note 
NEU3 transgenic mice develop impaired insulin 
signaling and insulin-resistant diabetes mellitus by 18-
22 weeks, associated with hyper-insulinemia, islet 
hyperplasia and increase in the beta-cell mass. As 
compared to the wild type, insulin-stimulated 
phosphorylation of the insulin receptor and insulin 
receptor substrate I is significantly reduced, and 
activities of phosphatidylinositol 3-kinase and glycogen 
synthase are also decreased. In muscle extracts, 
association of tyrosine-phosphorylated NEU3 with 
Grb2 occurs in response to insulin, together with 
accumulation of ganglioside GM1 and GM2. 
Involvement of NEU3 in cancer progression and 
development of diabetes suggests that these diseases 
might be closely related to each other in pathogenesis, 
given the recent epidemiological reports of higher 
cancer risk in diabetic patients than in controls. 
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